头孢噻呋钠在成年麻鸭体内的药动学研究

研究头孢噻呋钠在成年麻鸭体内的药动学特征及生物利用度,为临床制定合理的给药方案提供科学依据。选取24只健康的成年麻鸭(体重1.6?0.2kg),随机分为3组,以2mg.kg_-1剂量分别单次肌内注射、静脉注射和内服头孢噻呋钠,采用HPLC法检测血药浓度,计算头孢噻呋的药动力学参数和肌注、内服的生物利用度。结果表明：静脉注射头孢噻呋钠后,血药浓度经时数据符合二室开放模型,主要动力学参数：t_1/2α为0.19?0.22h,t_1/2β为3.64?0.22h,V_d为0.48?0.06L.kg_-1,CL为0.07?0.01 L.kg_-1.h_-1,AUC为27.09?2.84μg.mL_-1.h_-1;肌内注射后,血药浓度经时数据符合二室开放模型,主要动力学参数：t_1/2α为0.38?0.02h,t_1/2β为4.56?0.29h,T_max为0.49?0.17h,C_max为6.44?0.44μg.mL_-1,AUC为26.88?0.48μg.mL_-1.h_-1,生物利用度为99.22%;内服后,血药浓度经时数据符合二室开放模型,主要动力学参数：t_1/2α为0.77?0.14h,t_1/2β为3.81?0.23h,T_max为1.06?0.23h,C_max为3.62?0.20μg.mL_-1,AUC为21.47?0.44μg.mL_-1.h_-1,生物利用度为79.25%。头孢噻呋钠在成年麻鸭体内吸收迅速,半衰期较长,肌注的生物利用度高,内服吸收良好。     

氟苯尼考环糊精包合物的药动代谢动力学研究

健康白羽肉鸡20只,随机分为A、B两组,以20mg/kg的剂量单次灌服两种工艺的20%氟苯尼考粉。并于给药后不同时间点从翅下静脉采血,采用已建立的UPLC-MS/MS测定血浆中的药物浓度。采用 WinNonlin 5. 2. 1 药动学分析软件的非房室模型拟合血药浓度-时间数据。结果显示：A组达峰时间(Tmax)和达峰浓度(Cmax)分别为1.675±0.782 h、1073.20±425.72 ng/mL,平均消除半衰期T_1/2λz约为4.729±3.347 h,平均曲线下面积 (AUClast) 为 4498.76±2596.16 h?ng/mL;B组达峰时间(Tmax)和达峰浓度(Cmax)分别为1.523±1.723 h、4654.64±1669.75 ng/mL,平均消除半衰期T_1/2λz约为2.193±1.515 h,平均曲线下面积 (AUClast)为15392.84±2586.10 ng/mL;相对生物利用度约为342.16%。结果表明,采用环糊精包合工艺的氟苯尼考粉的生物利用度显著高于普通工艺的氟苯尼考粉。     

牛蒡子中牛蒡苷元在仔猪体内的药物动力学研究

为研究牛蒡子粉在仔猪体内的药物动力学特征,了解其在仔猪体内的吸收、分布、转化和排泄规律,为新兽药的研发和临床用药提供理论参考依据。选取健康仔猪8头(30.0±5.0kg),以1.0g/kg.bw的牛蒡子粉灌胃给药,不同时间点前腔静脉采血,采用HPLC法对猪血浆中牛蒡苷元的浓度进行分析。牛蒡子粉灌胃给药后,符合有吸收二室模型,主要药物动力学参数为：吸收半衰期(t_1/2ka)为0.274±0.102 h,分布半衰期(t_1/2α)1.435±0.725h;消除半衰期(t_1/2β)63.467±29.115 h;表观分布容积(V_d)1.680±0.402 L/kg;清除率(CL_b)0.076±0.028L/(h.kg);达峰时间(t_max)为0.853±0.211 h,峰浓度(c_max)为0.430±0.035μg /mL,药时曲线下面积(AUC)14.672±4.813μg.h/mL。试验表明：牛蒡子粉口灌后在仔猪体内吸收迅速、分布广泛、代谢消除缓慢,能够较长时间发挥药理作用。     

HPLC双波长法测定四味穿心莲散中穿心莲内酯和脱水穿心莲内酯的含量

目的：建立HPLC双波长法同时测定四味穿心莲散中穿心莲内酯和脱水穿心莲内酯的含量。方法：采用XBridge C₁₈色谱柱(4.6 mm×150 mm,5 μm),以甲醇-水(52:48)为流动相,流速1.0ml.min_-1^;柱温25℃;进样量10μL,检测波长分别为225nm(穿心莲内酯)和254nm(脱水穿心莲内酯)。结果：穿心莲内酯浓度在12.7375μg.mL_-1^～509.5μg.mL_-1^范围内,线性良好(r₂^=0.9996);脱水穿心莲内酯浓度在3.4μg.mL_-1^～136μg.mL_-1^范围内,线性关系良好(r₂^=0.9997)。穿心莲内酯加样回收率平均为98.8%,RSD 为1.0%;脱水穿心莲内酯回收率平均为99.9%,RSD 为0.8%。结论：该方法快捷、灵敏、准确、可靠,可用于四味穿心莲散中穿心莲内酯和脱水穿心莲内酯2个有效成分的同步测定,为四味穿心莲散的质量控制和评价提供科学依据。     

盐酸多西环素缓释注射液在猪体内的药物动力学

健康猪6头,体质量(17.85±1.3)kg,按拉丁方设计进行单剂量静注、肌注盐酸多西环素注射液(普通制剂)和肌注盐酸多西环素缓释注射液,注射剂量按多西环素计均为20 mg/kg,比较盐酸多西环素缓释注射液和盐酸多西环素注射液在猪体内的药动学特征和生物利用度.用高效液相色谱法测定其血药浓度,试验所得的血药浓度-时间数据采用非房室模型统计矩原理分析处理.猪静注盐酸多西环素注射液的主要药物动力学参数为AUC(108.15±13,25)mg·h·L-1,MRT(5.56±1.08)h,CI(0.19±0.02)L·h-1·kg-1,Vd(ss)(1.04±0.09)L·kg-1,t1/2(4.07±0.65)h.猪肌注盐酸多西环素注射液和盐酸多西环素缓释注射液的主要药物动力学参数分别为MRT(15.18±2.13)h和(22.25±3.49)h;Tmax(1.135±0.44)h和(2.0±0.63)h;Cmax(3.32±0.33)mg·L-1和(3.10±0.29)mg·L-1;AUC(38.91±4.35)mg·h·L-1和(61.72±10.16)mg·h·L-1;F(36.66±7.88)%和(57.66±10.75)%.比较盐酸多西环素注射液和盐酸多西环素缓释注射液的主要药动学参数,除了Cmax以外,MRT、Tmax、AUC、F等主要参数均有显著的统计学意义(P＜0.05).这表明盐酸多西环素缓释注射液肌注后吸收缓慢.消除半衰期延长,临床用药48 h给药1次仍能维持对常见病原菌的有效血药浓度.     

RP-HPLC测定注射液中甲硫酸新斯的明含量

建立了反向高效液相色谱法(RP-HPLC)测定注射液中甲硫酸新斯的明的含量。采用C18柱(4.6×150 mm,5 μm),以0.1%磷酸水溶液(用三乙胺调pH至3.0)-甲醇(90：10)为流动相,260 nm为检测波长。实验结果表明,甲硫酸新斯的明在10～2000 ng.mL_-1范围内线性关系良好,R₂=0.9999,平均回收率范围为99.2%～100.8％,RSD=0.52%。该方法简便、精确、重现性好,可用于甲硫酸新斯的明注射液的质量控制。     

福州地区橄榄低温冻害等级指标初步研究

本研究基于福州橄榄主要产区闽侯、闽清国家气象观测站1991～2020年冬季日极端最低气温和橄榄历史冻害资料,结合实地调查、统计分析、历史个例验证等方法,研究福州地区橄榄低温冻害的等级指标。结果将福州橄榄低温冻害等级指标初步确立为以下5个等级：无影响(0级):T_D≥-0.2 ℃、轻度(1级)-0.9 ℃≤T_D<-0.2 ℃、中度(2级)-1.7 ℃≤T_D<-0.9 ℃、重度(3级)-2.6 ℃≤T_D<-1.7 ℃、严重(4级)T_D<-2.6 ℃。以2020/2021年冬季发生冻害个例进行对比验证,发现按指标确定的冻害等级与实况判定等级一致的占50%,比实况等级偏高1级的占50%。研究结果表明该指标判定的冻害等级与实况吻合率较高,对橄榄生产过程中开展低温冻害预警服务具有一定的参考价值。     

云南玉溪产区柑橘树体营养状况分析

对云南省玉溪市4个代表性生态区的145个柑橘园春梢营养枝叶片矿质营养元素进行分析。结果表明,大量元素N、P、K的平均含量分别为3.03%、0.15%和1.32%,中量元素Ca、Mg、S的平均含量分别为4.46%、0.28%和0.30%,微量元素Fe、Mn、Zn、Cu、B的平均含量分别为145.94 mg.kg_-1、102.07 mg.kg_-1、16.79mg.kg_-1、19.83 mg.kg_-1、83.34 mg.kg_-1。N和Fe以超标为主,超标果园分别为56.55% 和62.76%;P、Ca、S、Mn、B以适量为主,适量果园分别占56.55%、80.69%、83.44%、52.41%、69.65%;Zn、Mg以不足为主,不足果园分别为88.28%和67.59%;K和Cu超标、适宜和不足果园比例约各占1/3。玉溪产区柑橘树体营养存在明显丰缺失衡状况,N、Fe超标和Mg、Zn不足问题突出,其它元素不足和超标比例也较高,生产上要控制N肥,补施 Mg、Zn肥,增施有机肥。     

离子色谱法测定酒石酸沃尼妙林中酒石酸的含量

目标：建立离子色谱-抑制电导检测法测定化学对照品中酒石酸盐的含量。方法：以酒石酸沃尼妙林对照品为例,采用DIONEX IonPac AS19(250 mm×4 mm)阴离子交换色谱柱和Ion Pac AS19保护柱(50 mm×4.0 mm),以22 mmol.L_-1^{氢氧化钾溶液为}流动相,流速为1.0 mL.min_-¹等度洗脱,抑制电导检测器检测,测定酒石酸盐中酒石酸的含量。结果：该方法在1.0~50 μg.mL_-1^{浓度范围内线性关系良好(}r=0.999),定量限为0.5μg.mL_-1^,酒石酸沃尼妙林在3个水平的加样回收率分别为98.79%、98.91%与96.50%,平均回收率为98.07% (RSD=2.20%,n=9)。用此方法测定3个厂家共5批样品,酒石酸沃尼妙林中酒石酸含量的数值与理论值基本一致。结论：本文建立的离子色谱法准确、灵敏,可用于酒石酸盐成盐比例与含量的测定。     

盐酸多西环素片在猪体内的残留消除规律研究

（目的）研究盐酸多西环素片按说明书给药后在猪体内的残留消除规律并确定休药期。（方法）将多西环素片以5 mg/kg体重口服给药，间隔24 h，连续给药5次。最后一次给药之后分别在第0日（12 h）、1日、3日、6日和8日时间点采集猪的肌肉、肝脏、肾脏和脂肪，采用建立并验证的HPLC-VWD法测定猪不同组织中多西环素的含量。（结果）方法学考察结果表明，在0.05-5 μg/mL添加范围内的线性方程和相关系数为Y=0.044x-0.414，R2=0.999。不同组织中的盐酸多西环素的平均回收率在60.32%~116.80%。（结论）为保证兽药使用安全、食品安全与人民健康，建议按照休药期计算结果确定盐酸多西环素片在猪体内的休药期为7日。     

Orally administered doxycycline accumulates in synovial fluid compared to plasma

Reasons for performing study: Tetracycline compounds have been used to slow the progression of osteoarthritis (OA) and rheumatoid arthritis but the concentration of doxycycline attained in synovial fluid following oral, low‐dose administration has yet to be determined. Objective: To determine the concentration of doxycycline in synovial fluid following oral, low‐dose administration. Methods: Six mature horses received doxycycline (5 mg/kg bwt q. 12 h for 5 doses). Venous blood and synovial fluid samples were collected at t = 0, 0.25, 0.5, 1, 12, 24, 48 and 72 h. Doxycycline concentrations were measured using reverse phase high pressure liquid chromatography with ultraviolet detection. Results: Doxycycline concentrations at all time points after t = 0 were above the lower limit of quantification for the assay. Plasma concentrations of doxycycline were above 0.21 µg/ml at t = 0.5 h. The mean ± s.d. peak concentration (C_max) of doxycycline in plasma was 0.37 ± 0.22 µg/ml and time to peak concentration was 0.54 ± 0.19 h. Synovial fluid concentrations of doxycycline were above 0.12 µg/ml 1 h after drug administration. The mean C_max of doxycycline in the synovial fluid was 0.27 ± 0.10 µg/ml. The penetration factor of doxycycline from plasma into synovial fluid, as determined by a ratio of the area‐under‐the‐curve for synovial fluid:plasma during the sampling period, was 4.6. Potential relevance: Orally administered doxycycline distributes easily into synovial fluid with a penetration factor of 4.6. Terminal half‐life of the drug in synovial fluid was longer than in the plasma, indicating possible accumulation in this compartment. Further in vivo studies are warranted to define a medication protocol prior to routine clinical use of doxycycline for the treatment of OA.     

Pharmacokinetics of doxycycline after a single intravenous,oral or intramuscular dose in Muscovy ducks (Cairina moschata)

1. The pharmacokinetics of doxycycline in ducks were investigated after a single intravenous (IV), intramuscular (IM) or oral (PO) dose at 20 mg/kg body weight.

2. The concentrations of doxycycline in plasma samples were assayed using a high performance liquid chromatography method, and pharmacokinetic parameters were calculated using a non-compartmental model.

3. After IV administration, doxycycline had a mean (±SD) distribution volume (V_z) of 1761.9 ± 328.5 ml/kg and was slowly eliminated with a terminal half-life (t_1/2λz) of 21.21±1.47 h and a total body clearance (Cl) of 57.51 ± 9.50 ml/h/kg. Following PO and IM administration, doxycycline was relatively slowly absorbed – the peak concentrations (C_max) were 17.57 ± 4.66 μg/ml at 2 h and 25.01 ± 4.18 μg/ml at 1.5 h, respectively. The absolute bioavailabilities (F) of doxycycline after PO and IM administration were 39.13% and 70.71%, respectively.

4. The plasma profile of doxycycline exhibited favourable pharmacokinetics characteristics in Muscovy ducks, such as wide distribution, relatively slow absorption and slow elimination, though oral bioavailability was low.

     

Pharmacokinetics of doxycycline in laying hens after intravenous and oral administration

1. The pharmacokinetics of doxycycline in laying hens was investigated after a single intravenous (IV) or an oral (PO) dose at 20 mg/kg body weight.

2. The concentrations of doxycycline in plasma samples were determined by high-performance liquid chromatography with an ultraviolet detector, and pharmacokinetic parameters were calculated using a compartmental model method.

3. The disposition of doxycycline after one single IV injection was best described by a two-compartment open model and the main pharmacokinetic parameters were as follows: volume of distribution (V_d) was 865.15 ± 127.64 ml/kg, distribution rate constant (α) was (2.28 ± 0.38) 1/h, elimination rate constant (β) was 0.08 ± 0.02 1/h and total body clearance (Cl) was104.11 ± 18.32 ml/h/kg, while after PO administration, the concentration versus time curve was best described by a one-compartment open model and absorption rate constant (K_a), peak concentration (C_max), time to reach C_max (t_max) and absolute bioavailability (F) were 2.55 ± 1.40 1/h, 5.88 ± 0.70 μg/ml, 1.73 ± 0.75 h and 52.33%, respectively.

4. The profile of doxycycline exhibited favourable pharmacokinetic characteristics in laying hens, such as quick absorption and slow distribution and elimination, though oral bioavailability was relatively low. A multiple-dosing regimen (a dose of 20 mg/kg/d for 3 consecutive days) of doxycycline was recommended to treat infections in laying hens. But a further study should be conducted to determine the withdrawal time of doxycycline in eggs.

     

Pharmacokinetics of doxycycline in tilapia (Oreochromis aureus × Oreochromis niloticus) after intravenous and oral administration

The pharmacokinetics of doxycycline was studied in plasma after a single dose (20 mg/kg) of intravenous or oral administration to tilapia (Oreochromis aureus × Oreochromis niloticus) reared in fresh water at 24 °C. Plasma samples were collected from six fish per sampling point. Doxycycline concentrations were determined by high‐performance liquid chromatography with a 0.005 μg/mL limit of detection, then were subjected to noncompartmental analysis. Following oral administration, the double‐peak phenomenon was observed, and the first (C_max1) and second (C_max2) peaks were 1.99 ± 0.43 μg/mL at 2.0 h and 2.27 ± 0.38 μg/mL at 24.0 h, respectively. After the intravenous injection, a C_max2 (12.12 ± 1.97 μg/mL) was also observed, and initial concentration of 45.76 μg/mL, apparent elimination rate constant (λ_z) of 0.018 per h, apparent elimination half‐life (t_1/2λz) of 39.0 h, systemic total body clearance (Cl) of 41.28 mL/h/kg, volume of distribution (Vz) of 2323.21 mL/kg, and volume of distribution at steady‐state (Vss) of 1356.69 mL/kg were determined, respectively. While after oral administration, the λ_z, t_1/2λz, and bioavailability of doxycycline were 0.009 per h, 77.2 h, and 23.41%, respectively. It was shown that doxycycline was relatively slowly and incompletely absorbed, extensively distributed, and slowly eliminated in tilapia, in addition, doxycycline might undergo enterohepatic recycling in tilapia.     

乳酸恩诺沙星可溶性粉在鸡体内的药动学研究

24只苏禽黄羽肉鸡随机分成2组,分别按10 mg/kg体重剂量静注和内服乳酸恩诺沙星。测定乳酸恩诺沙星在鸡体内的药动学参数和生物利用度。恩诺沙星血药浓度数据用3p87计算机软件处理。静注乳酸恩诺沙星后的血药浓度-时间数据符合二室开放模型,主要动力学参数:t1/2α(0.45±0.16)h,t1/2β(7.02±1.42)h,CL(s)(0.38±0.10)L/kg/h,AUC(23.69±5.56)(mg/L)×h。内服乳酸恩诺沙星的血药浓度时间数据,符合有吸收因素二室模型,主要动力学参数:t1/2ka(0.60±0.01)h,t1/2ke(8.25±1.73)h,tpeak(2.44±0.17)h,Cmax(1.44±0.30)mg/L,AUC(20.74±3.80)(mg/L)×h,F 87.54%。结果表明,乳酸恩诺沙星可溶性粉在鸡体内具有吸收快、分布广、消除较慢以及内服生物利用度高的药动学特征。     

Ocular penetration of oral doxycycline in the horse

OBJECTIVE: To investigate intraocular penetration of orally administered doxycycline in the normal equine eye and to compare intraocular and serum doxycycline concentrations. Procedures Six mares were administered doxycycline at 10 mg/kg every 12 h by nasogastric tube for 5 days. Blood, aqueous, and vitreous samples were collected on days 1 and 5. All samples were assayed for doxycycline concentrations. Aqueous and vitreous samples were also assayed for protein quantitation. RESULTS: Doxycycline was rapidly absorbed after the first dose (T(max) value of 1.42 +/- 1.28 h); and elimination of doxycycline occurred slowly (median t(1/2) = 10.88 h). Doxycycline could not be detected in the aqueous on days 1 and 5, nor could it be detected in the vitreous on day 1. On day 5, the mean vitreous doxycycline concentration was 0.17 +/- 0.04 microg/mL at 2 h after drug administration. CONCLUSIONS: Repeated oral administration of doxycycline in the horse resulted in steady state serum concentrations of < 1 microg/mL; however, it did not result in appreciable concentrations of drug in the aqueous and vitreous in normal eyes.     

Pharmacokinetics of oxytetracycline and therapeutic implications in veal calves

Pharmacokinetic parameters of oxytetracycline were analysed in healthy preruminant veal calves after intravenous, intramuscular and oral administration. The serum half-lives in the β-elimination phase of both 10% and 20% solutions after i.v. injection of 10 mg/kg were similar (7.07 ± 1.36 h and 7.16 ± 1.17 h, mean ± SD), whereas the total body clearance and the apparent volume of distribution were higher for the 20% solution. Serum concentrations above 0.5 μg/ml were maintained with both formulations during 12–24 h but were only above 4 μg/ml to 5 h. Intramuscular administration of the 20% solution gave a complete absorption with two rate constants of absorption, a faster (t_1/2a1= 0.27 h) and a slower one (t_1/2a2= 10.90 h) responsible for the delayed elimination half-life after this route of application (t_1/2β= 9.83 ± 1.35 h). Mean serum concentrations reached a maximum level of 3.01 ± 0.72 μg/ml at 4.01 ± 2.84 h and decreased to 0.5 μg/ml between 12 and 24 h. 50 mg/kg given orally with a milk replacer were found to have a mean bioavailability of 46.35%. A mean serum peak level of 4.99 ± 1.37 μg/ml was achieved at 9.16 ± 1.99 h and the mean concentration was still above 0.5 μg/ml after 48 h. The elimination half-life (t_1/2β= 10.66 ± 3.15 h) reflected the slow absorption step (t_1/2a2= 10.15 h) following that responsible for the initial faster absorption (t_1/2a2= 1.99 h). Comparison of the area under the serum curves gave mean values of 117% for tetracycline and of 53% for chlortetracycline relative to oxytetracycline (arbitrarily fixed at 100%) after identical oral dosage of the three tetracyclines. We also propose and discuss a dosage schedule based on minimal inhibitory concentrations of different susceptible pathogens     

Pharmacokinetics of allopurinol in Dalmatian dogs

The pharmacokinetics of allopurinol were studied in Dalmatian dogs. Eight dogs were given allopurinol orally at a dose of 10 mg/kg for seven doses prior to sample collection. After a period of at least two weeks, four of these dogs and four additional Dalmatians were later given a single intravenous (i.v.) dose of allopurinol (6 mg/kg) prior to sample collection.Allopurinol was found to follow first-order absorption and elimination kinetics. In the i.v. kinetic study, the elimination constant (K_el) = 0.31±0.03 per h, the half-life (t_½) = 2.22±0.20 h, the initial concentration (C₀) = 5.26±0.34 μg/mL and the specific volume (V_d) = 1.14±0.07 L/kg. Clearance of allopurinol was estimated to be 0.36±0.03 L/kg·h. In the oral kinetic study, the absorption rate constant (K_ab) = 1.06±0.13 per h, the elimination rate constant (K_el) = 0.26±0.01 per h, the absorption half-life (t_½ab) = 0.66±0.06 h, and the elimination half-life (t_½el) = 2.69±0.14 h. Peak plasma concentrations (C_max) = 6.43±0.18 μg/mL were obtained within 1 to 3 h (mean time of maximum concentration (T_max) = 1.9±0.1 h). The volume of distribution corrected by the fraction of dose absorbed (V_d/F) was estimated to be 1.17±0.07 L/kg.Good agreement was obtained between mean kinetic parameters in the oral and i.v. studies. There was little variation between individual dogs in the i.v. study, whereas the rate of absorption and elimination of orally administered allopurinol was more varied among individual dogs. Because of this, and the fact that the magnitude of hyperuricosuria varies among Dalmatians, it is not possible to specify an exact dose of allopurinol that will effectively lower the urinary uric acid concentration to acceptable values in all Dalmatians with hyperuricosuria; rather, the dose must be titrated to the needs of each dog.     

A comparative study of the pharmacokinetics of intravenous and oral trimethoprim/sulfadiazine formulations in the horse

The biopharmaceutical properties of four fuced trimethoprim/sulfonamide combinations were investigated in the horse. Eight fasted horses were dosed at 1 week intervals in a sequentially designed study with one intravenous (i.v.) and three oral trimethoprim/sulfadiazine (TMP/SDZ) formulations (1, 2 and 3) administered at a dose of 5 mg/kg trimethoprim (TMP) and 25 mg/kg sulfadiazine (SDZ). Plasma concentrations of each compound were monitored for 48 h. Pharmacokinetic parameters (volume of distribution, bioavailability and total body clearance) for TMP and SDZ were calculated and compared. After oral administration plasma concentrations of TMP and SDZ increased rapidly. With all three paste formulations, TMP peak plasma concentrations were attained within 2 h. SDZ mean peak plasma concentrations were reached at 2.59 ± 0.48 h for a commercial paste (l), and at 1.84 ± 0.66 h and 1.95 ± 0.61 h for the two self-made formulations (2 and 3). Mean peak plasma TMP concentrations (± SD) were 1.72 ± 0.36 μg/ml, 1.42 ± 0.37 μg/ml and 1.31 ± 0.36 μ g/d, and mean peak plasma SDZ concentrations 12.11 ± 4.5 5 μg/ml, 12.72 ± 3.47 μg/ml and 15.45 ± 4.74 μg/ml for preparations 1, 2 and 3. The bioavailability of TMP was 67.0 ± 20.3%, 57.7 ±21.6% and 60.9 f 18.9% and of SDZ 57.6 ± 14.8%, 59.3 ± 19.5% and 65.9 ± 5.8% for SDZ for 1, 2 and 3, respectively. Following i.v. administration TMP/SDZ plasma concentration ratios approached the optimal 1:20 ratio (It 10%) for about 5 h, but following the oral administrations this ratio was only achieved for a very short time-span. No adverse effects were seen following i.v. and oral administration. In considering the pharmacokinetic data in combination with in vitro antibacterial sensitivity data, it is concluded that treatment at a dose of 5 mg/kg TMP and 25 mg/kg SDZ with a dosing interval of 12 h can be regarded as therapeutically effective for susceptible bacteria (MIC₉₀ 0.25/4.75) for all three oral formulations. It is concluded that neither the formulation nor the addition of different excipients result in significantly different bioavailabilities.     

The pharmacokinetics of cefadroxil over a range of oral doses and animal ages in the foal

To evaluate the effect of foal age on the pharmacokinetics of cefadroxil, five foals were administered cefadroxil in a single intravenous dose (5 mg/kg) and a single oral dose (10 or 20 mg/kg) at ages of 0.5, 1, 2, 3 and 5 months. Pharmacokinetic parameters of terminal elimination rate constant (β_po), oral mean residence time (MRT_po), mean absorption time (MAT), rate constant for oral absorption (K_a), bioavailability F, peak serum concentrations(C_max) and time of peak concentration (t_max), were evaluated in a repeated measures analysis over dose. Across animal ages, parameters for the intravenous dose did not change significantly over animal age (P 0.05). Mean values ± SEM were: β_IV = 0.633 ± 0.038 h^?1; Cl = 0.316 ± 0.010 L/kg/h; V_c = 0.196 ± 0.008 L/kg; V_area = 0.526 ± 0.024 L/kg; V_SS =0.374 ± 0.014 L/kg; MRT_iv = 1.22 ± 0.07 h; K_el = 1.67 ± 0.08 ^h?1. Following oral administration, drug absorption became faster with age (P < 0.05), as reflected by MRT_po, MAT, K_a and t_max. However, oral bioavailability (±SE) declined significantly (P < 0.05) from 99.6 ± 3.69% at 0.5 months to 14.5 ± 1.40% at 5 months of age. To evaluate a dose effect on the pharmacokinetic parameters, a series of oral doses (5, 10, 20 and 40 mg/kg) were administered to these foals at 1 month of age. β_po (0.548 ± 0.023 h^?1) and F (68.26 ± 2.43%) were not affected significantly by the size of the dose. C_max was approximately doubled with each two-fold increase in dose: 3.15 ± 0.15, 5.84 ± 0.48, 12.17 ± 0.93 and 19.71 ± 2.19 μg/mL. Dose-dependent kinetics were observed in MRT_po, MAT, K_a and t_max.